CrushSCI.com
Journal Selection & Manuscript Polishing Services
Molecular Therapy Oncology journal cover Medicine
Back to journal directory

Review Cycle Records

Molecular Therapy Oncology

Elsevier SCIE Non-OA
2026 Emerging Zone 22025 CAS No data2025 JCR Q1
184.1Average days
159Median days
55Fastest days
490Longest days
1642025 publications

Paper Review Records

All Paper Review Records

10 valid samples · Newest publication first
Review days = acceptance date − received date. PDF, DOI, and publisher-page sources are retained.

109 days

USP15 regulates mitotic fidelity, metastatic potential, and chemotherapeutic response in ovarian cancer cells

AuthorsAyokunnumi Ogunsanya; Fatimah Alfaran; Omuya Noel Amadu; Achuth Padmanabhan

AffiliationsDepartment of Biological Sciences, University of Maryland Baltimore County, Baltimore, MD, USA; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, MD, USA

Source PDF DOI Publisher page
159 days

Ultrasound controllable and antigen-independent killing via cis-activating CAR T cells

AuthorsLinshan Zhu; Jiaxin Cui; Chi-Wei Man; Anthony Mouchawar; Xi Yu; Yixuan Huang; Yiqian Wu; Tianze Guo; Hongquan Xu; Longwei Liu; Yingxiao Wang

AffiliationsAlfred E. Mann Department of Biomedical Engineering, University of Southern California, Los Angeles, Los Angeles, CA 90089, USA; Department of Chemistry and Biochemistry, University of California, San Diego, La Jolla, CA 92093, USA; Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 90089, USA; National Biomedical Imaging Center, College of Future Technology, Peking University, Beijing 100871, China; Department of Statistics, University of California, Los Angeles, Los Angeles, CA 90095, USA; Department of Ophthalmology, Roski Eye Institute, Keck School of Medicine, University of Southern California, Los Angeles, Los Angeles, CA 90033, USA; Department of Bioengineering and Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA 92093, USA

Source PDF DOI Publisher page
260 days

Simultaneous targeting of IL-10 and PD-(L)1 pathways with a bispecific anti-PD-L1/IL-10-trap antibody enhances T cell responses

AuthorsLatika Singh; Natalia Zabavnik; Sambasivan Venkatasubramanian; Sagi Barzilai; Jing Ni; Andreas Evers; Olga Bogatyrova; Melissa G. Derner; Stefan Zielonka; Rinat Zaynagetdinov; Laura Helming

AffiliationsResearch Unit Oncology, EMD Serono Research and Development Institute, Inc., Billerica, MA 01821, USA; Antibody Discovery and Protein Engineering, Inter-Lab Ltd., Yavne 8122004, Israel; Research Unit Oncology, the Healthcare Business of Merck KGaA, 64293 Darmstadt, Germany; Antibody Discovery and Protein Engineering, the Healthcare Business of Merck KGaA, 64293 Darmstadt, Germany; Research Unit Oncology Data Science, the Healthcare Business of Merck KGaA, 64293 Darmstadt, Germany

Source PDF DOI Publisher page
182 days

Synergistic cell-cycle repression by HDAC/EZH2 co-targeting in H3K27-altered diffuse midline glioma

AuthorsZili Zhen; Qiang Gao; Yong Ai; Zhihong Qian; Yukui Shang; Yafang Deng; Shuai Chen; Xin Ni; Wei Zhang

AffiliationsIDG/McGovern Institute for Brain Research, School of Life Sciences, Tsinghua University, Beijing 100084, China; Department of Neurosurgery, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750003, China; School of Clinical Medicine, Tsinghua Medicine, Tsinghua University, Beijing 100084, China; Department of Neurosurgery, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; The State Key Laboratory for Complex, Severe, and Rare Diseases, School of Basic Medical Sciences, Tsinghua Medicine, Tsinghua University, Beijing 100084, China; Department of Internal Medicine, Peking Union Medical College Hospital, Beijing 100730, China; Neurological Center, Beijing Children’s Hospital Shunyi Women’s and Children’s Hospital, Beijing 101300, China; National Center for Pediatric Cancer Surveillance, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China; Clinical Research Center, Beijing Children’s Hospital, Capital Medical University, National Center for Children’s Health, Beijing 100045, China

Source PDF DOI Publisher page
106 days

Neuroepithelial reprogramming and ERBB vulnerability in canine acanthomatous ameloblastoma

AuthorsAndreas Stephanou; Bo Shui; Deanna Mische; Michael Byron; William P. Katt; Marina Chan; Jennifer K. Grenier; Iwijn De Vlaminck; Gerald E. Duhamel; Taranjit S. Gujral; Praveen Sethupathy; Santiago Peralta

AffiliationsDepartment of Biomedical and Translational Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14853, USA; Nancy E. and Peter C. Meinig School of Biomedical Engineering, Cornell University, Ithaca, NY 14853, USA; Human Biology Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA; Department of Clinical Sciences, Clinical Programs Center, College of Veterinary Medicine, Cornell University, Box 31, Ithaca, NY 14853, USA; Biotechnology Resource Center, Cornell University, Ithaca, NY 14853, USA

Source PDF DOI Publisher page
168 days

TAP1 deficiency reshapes tumor antigenicity and enables CD8 T cell targeting in colorectal cancer

AuthorsAudrey Merienne; Kathleen Ducoin; Cécile Deleine; Mathilde Deiber; Margot Machu; Edouard Leveque; Romain Oger; Emilie Duchalais; Pierre Fourquier; Céline Bossard; Nathalie Labarrière; Houssem Benlalam; Anne Jarry; Nadine Gervois-Segain

AffiliationsNantes Université, University Angers, CHU Nantes, INSERM, CNRS, Immunology and New Concepts in ImmunoTherapy, INCIT, UMR 1302/EMR6001, 44000 Nantes, France; LabEx IGO and ImmuNE, Nantes Université, Nantes, France; IRCM, University Montpellier, Inserm, ICM, CNRS, Montpellier, France; University of Toulouse, Infinity, Inserm, CNRS, 31024 Toulouse, France; Nantes Université, University Angers, INSERM, CNRS, Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers, CRCI2NA, UMR 1307/EMR6001, 44000 Nantes, France; Department of Digestive Surgery and IMAD, CHU Nantes, France; Department of Digestive Surgery, Hôpital Privé Du Confluent, Nantes, France; Department of Pathology, CHU Nantes, IHP Group, Nantes, France

Source PDF DOI Publisher page
153 days

Oncolytic adenovirus incorporating TetO sites in the E1A promoter for controlled replication in TetR-expressing mesenchymal stem cells

AuthorsRamon Alemany; Silvia Torres-Manjon; Laia Traveset; Rafael Moreno

AffiliationsCancer Immunotherapy Group, Oncobell and IProCURE programs, IDIBELL-Institut Català D'Oncologia, L'Hospitalet de Llobregat, Barcelona, Spain; Innovation unit, Business Development and Innovation area, IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain

Source PDF DOI Publisher page
490 days

Reversible control of CAR T cells through PROTAC compound targeting bromodomain mutant

AuthorsYeongrin Kim; Da Yeon Lee; Ji U. Choi; Moonjung Jeun; Heung Kyoung Lee; Sang Un Choi; Chi Hoon Park

AffiliationsData Convergence Drug Research Center, Korea Research Institute of Chemical Technology, Daejeon 34114, Republic of Korea; College of Pharmacy, Chungnam National University, Daejeon 34134, Republic of Korea; Medicinal Chemistry and Pharmacology, University of Science and Technology, Daejeon 34113, Republic of Korea

Source PDF DOI Publisher page
55 days

Feasibility and outcomes of decentralized point-of-care CD19 CAR T cell for relapsed large B cell lymphoma in resource-limited settings

AuthorsKoramit Suppipat; Supannikar Tawinwung; Ornnicha Sathitakorn; Chantiya Chanswangphuwana; Kanhatai Chiengthong; Mutita Surakijboworn; Thiti Asawapanumas; Phandee Watanaboonyongcharoen; Palada Pitakkitnukun; Manaschanok Tippawan; Supanat Kumjan; Udomsak Bunworasate; Nattiya Hirankarn; Kitsada Wudhikarn

AffiliationsCenter of Excellence in Cellular Immunotherapy, Chulalongkorn University, Bangkok 10330, Thailand; Department of Research Affairs, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; Department of Pharmacology and Physiology, Faculty of Pharmaceutical Sciences, Chulalongkorn University, Bangkok 10330, Thailand; Division of Hematology and Center of Excellence in Translational Hematology, Department of Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; Division of Pediatric Hematology and Oncology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; Center of Excellence in Pediatric Hematology/Oncology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; Department of Laboratory Medicine, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand; Transfusion Medicine Unit, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand; Transplant and Cellular Therapy Unit, King Chulalongkorn Memorial Hospital, Bangkok 10330, Thailand; Center of Excellence in Immunology and Immune-Mediated Diseases, Department of Microbiology, Faculty of Medicine, Chulalongkorn University, Bangkok 10330, Thailand

Source PDF DOI Publisher page
159 days

Augmenting CAR T cell functionality and metabolism through CD39 downtuning

AuthorsDennis Christoph Harrer; Jeremy Baldwin; Markus Barden; Hong Pan; Bence Gergely; Árpád Szöőr; György Vereb; Wolfgang Herr; Hinrich Abken

AffiliationsDepartment of Hematology and Internal Oncology, University Hospital Regensburg, 93053 Regensburg, Germany; Leibniz Institute for Immunotherapy, Div. Genetic Immunotherapy, Chair Genetic Immunotherapy, University Regensburg, 93053 Regensburg, Germany; Leibniz Institute for Immunotherapy, Div. Functional Immune Cell Modulation, University Regensburg, 93053 Regensburg, Germany; Department of Pathology, University of Cambridge, Cambridge CB2 1QP, UK; Department of Biophysics and Cell Biology, University of Debrecen Faculty of Medicine, 4032 Debrecen, Hungary; University of Debrecen Faculty of Pharmacy, 4032 Debrecen, Hungary

Source PDF DOI Publisher page

Expert Matching · Case Demo

Turn Your Submission Goalsinto a Verifiable Journal Plan

Share your field, deadline, and author profile. CrushSCI uses real review records to suggest a title direction, shortlist journals, and estimate timelines.

CrushSCI online

Client

I work in environmental engineering and need an SCI paper published within three months. I have no grant funding or prominent co-author. Which journals could I target?

CrushSCI

Yes. We will first screen for feasibility against the 90-day deadline, then identify comparable papers without grant support or prominent co-authors. The final shortlist will prioritize research quality and journal scope.

Suggested title
Machine Learning and Life-Cycle Assessment for Predicting and Optimizing Carbon Emissions in Urban Wastewater Treatment

SampleLatest 5 valid paper samples from 2026

Average review96.4 days

Median77 days

Contact CrushSCI

Contact CrushSCI

Leave your contact details so we can discuss your manuscript, editing needs, and submission plan.

Selected service: Paper Editing Service

Or leave your contact details

WhatsApp, Telegram, WeChat, and email are all optional, but at least one is required. Once received, we will contact you as soon as possible.